• Recruiting

NCT03758417: Phase 2 - LCAR-B38M CAR-T Cells Against BCMA in Chinese relapsed Myeloma (CARTIFAN - 1)

Updated: Sep 2

The purpose of this study is to evaluate the efficacy and safety of LCAR-B38M chimeric antigen receptor T (CAR-T) cells.

CARTIFAN - 1

CHINESE STUDY


A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma (CARTIFAN-1)


Sponsor

Nanjing Legend Biotech Co.

Legend Biotech


Collaborator

Janssen Research & Development, LLC

 

ClinicalTrials.gov Identifier: NCT03758417


Official Title: A Phase 2, Open-Label Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against BCMA in Chinese Subjects With Relapsed or Refractory Multiple Myeloma


First Posted : November 29, 2018


Click here for details on ClinicalTrials.gov

 

CART - BCMA : National Cancer Institute

JNJ-68284528 - ciltacabtagene autoleucel

LCAR-B38M

 

Location

China

China, Beijing

China, Fujian

China, Jiangsu

China, Shanghai

China, Shanxi

China, Sichuan

China, Zhejiang









Posts Archive